Post-translational modifications and immune responses in liver cancer

Post-translational modification (PTM) refers to the covalent attachment of functional groups to protein substrates, resulting in structural and functional changes. PTMs not only regulate the development and progression of liver cancer, but also play a crucial role in the immune response against cancer. Cancer immunity encompasses the combined efforts of innate and adaptive immune surveillance against tumor antigens, tumor cells, and tumorigenic microenvironments. Increasing evidence suggests that immunotherapies, which harness the immune system’s potential to combat cancer, can effectively improve cancer patient prognosis and prolong the survival. This review presents a comprehensive summary of the current understanding of key PTMs such as phosphorylation, ubiquitination, SUMOylation, and glycosylation in the context of immune cancer surveillance against liver cancer. Additionally, it highlights potential targets associated with these modifications to enhance the response to immunotherapies in the treatment of liver cancer.

[1]  Chenyang Han,et al.  LncRNA PSCK6-AS1-HIPK2 promotes Th1 differentiation via STAT1 phosphorylation to regulate colitis-related mucosal barrier damage. , 2023, International immunopharmacology.

[2]  L. Butterfield,et al.  Polyunsaturated Fatty Acid–Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism , 2023, Cancer Research.

[3]  M. Jücker,et al.  The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism , 2023, International journal of molecular sciences.

[4]  Jianfei Huang,et al.  KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma. , 2023, Colloids and surfaces. B, Biointerfaces.

[5]  Ying-Ying Li,et al.  Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma , 2022, Cell Communication and Signaling.

[6]  Juejin Wang,et al.  Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Q. Zhang,et al.  IL-2–mTORC1 signaling coordinates the STAT1/T-bet axis to ensure Th1 cell differentiation and anti-bacterial immune response in fish , 2022, PLoS pathogens.

[8]  M. Caligiuri,et al.  Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. , 2022, Trends in immunology.

[9]  J. Ferlay,et al.  Global burden of primary liver cancer in 2020 and predictions to 2040 , 2022, Journal of hepatology.

[10]  C. Pang,et al.  Post-translational modifications on the retinoblastoma protein , 2022, Journal of Biomedical Science.

[11]  Xiaolong Yan,et al.  Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy , 2022, Frontiers in Immunology.

[12]  Xinglu Huang,et al.  Combining Doxorubicin-Conjugated Polymeric Nanoparticles and 5-Aminolevulinic Acid for Enhancing Radiotherapy against Lung Cancer. , 2022, Bioconjugate chemistry.

[13]  G. Wang,et al.  Mechanism of cancer stemness maintenance in human liver cancer , 2022, Cell death & disease.

[14]  M. Mariappan,et al.  A second chance for protein targeting/folding: Ubiquitination and deubiquitination of nascent proteins , 2022, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  L. Nath,et al.  Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma. , 2022, Current cancer drug targets.

[16]  P. Khare,et al.  Role of interleukin-17 in human papillomavirus infection and associated malignancies. , 2021, Microbial pathogenesis.

[17]  Xinyi Li,et al.  Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy , 2021, International journal of molecular sciences.

[18]  Tieliang Ma,et al.  Dexmedetomidine Directs T Helper Cells toward Th1 Cell Differentiation via the STAT1-T-Bet Pathway , 2021, BioMed research international.

[19]  Y. Pathak,et al.  A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions , 2021, Frontiers in Immunology.

[20]  F. Pan,et al.  Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications , 2021, Frontiers in Immunology.

[21]  Pravir Kumar,et al.  Post-translational modifications: Regulators of neurodegenerative proteinopathies , 2021, Ageing Research Reviews.

[22]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[23]  I. Wertz,et al.  Ubiquitination in the regulation of inflammatory cell death and cancer , 2021, Cell Death & Differentiation.

[24]  D. Nayak,et al.  Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis , 2020, International journal of molecular sciences.

[25]  Haojun Yang,et al.  Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma , 2020, Frontiers in Oncology.

[26]  E. Yeh,et al.  SUMO: From Bench to Bedside. , 2020, Physiological reviews.

[27]  N. Tang,et al.  2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1 , 2020, Journal for ImmunoTherapy of Cancer.

[28]  Jeffrey S. Miller,et al.  Exploring the NK cell platform for cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.

[29]  Matthias J. Feige,et al.  Influence of glycosylation on IL-12 family cytokine biogenesis and function. , 2020, Molecular immunology.

[30]  P. Wei,et al.  Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. , 2020, Immunity.

[31]  Dawang Zhou,et al.  Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment. , 2020, Molecular cell.

[32]  Qingjiao Li,et al.  MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing , 2020, Nature Communications.

[33]  Zhuanchang Wu,et al.  Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by disrupting PI3K signaling. , 2019, Cancer research.

[34]  P. Adusumilli,et al.  Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. , 2019, Cancer cell.

[35]  Manal M. Hassan,et al.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. , 2019, The Journal of clinical investigation.

[36]  B. Shi,et al.  Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma , 2019, The Journal of Immunology.

[37]  Clare C. Davies,et al.  PRMTs and Arginine Methylation: Cancer's Best-Kept Secret? , 2019, Trends in molecular medicine.

[38]  Hong Tang,et al.  Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression , 2019, Journal of Hematology & Oncology.

[39]  Jing Wang,et al.  The deubiquitinase Otub1 controls the activation of CD8 T cells and NK cells by regulating IL-15-mediated priming , 2019, Nature Immunology.

[40]  Yun Yang,et al.  SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway , 2019, OncoTargets and therapy.

[41]  J. Jang,et al.  Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization , 2019, Scientific Reports.

[42]  Yulin Zhao,et al.  RETRACTED ARTICLE: NEAT1 regulates Th2 cell development by targeting STAT6 for degradation , 2019, Cell cycle.

[43]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[44]  Yu Xue,et al.  PTMD: A Database of Human Disease-associated Post-translational Modifications , 2018, Genom. Proteom. Bioinform..

[45]  M. Tao,et al.  Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment , 2018, Oncoimmunology.

[46]  Peng Li,et al.  New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF‐NRP‐1 axis and inhibit tumor growth in vivo , 2018, International immunopharmacology.

[47]  Leo Swadling,et al.  IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction , 2018, Front. Immunol..

[48]  J. Zhao,et al.  Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value , 2017, Medicine.

[49]  Giuseppe Troiano,et al.  The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) , 2017, International journal of molecular medicine.

[50]  Wei Jia,et al.  The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion , 2017, Nature Communications.

[51]  K. Guo,et al.  Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells , 2017, Oncology letters.

[52]  L. Hui,et al.  STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. , 2015, The Journal of clinical investigation.

[53]  Charles Bailey,et al.  Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic Strategies , 2015, Viruses.

[54]  J. Abastado,et al.  TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression , 2015, Oncotarget.

[55]  Seung-Hwan Lee,et al.  IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells , 2015, Front. Immunol..

[56]  Z. Tian,et al.  Re-examining the origin and function of liver-resident NK cells. , 2015, Trends in immunology.

[57]  L. Butterfield,et al.  Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells , 2014, The Journal of Immunology.

[58]  A. Ciechanover,et al.  A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. 1978. , 2012, Biochemical and Biophysical Research Communications - BBRC.

[59]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[60]  Alicia M Bielik,et al.  Identification and characterization of protein glycosylation using specific endo- and exoglycosidases. , 2011, Journal of visualized experiments : JoVE.

[61]  Q. Gao,et al.  IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma , 2011, Molecular Cancer.

[62]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[63]  D. Ye,et al.  Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2 , 2011, Oncogene.

[64]  R. Deshaies,et al.  RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.

[65]  A. Philpott,et al.  Ubiquitylation on Canonical and Non-canonical Sites Targets the Transcription Factor Neurogenin for Ubiquitin-mediated Proteolysis* , 2009, The Journal of Biological Chemistry.

[66]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[67]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[68]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[69]  W. Paul,et al.  Stat6 Is Necessary and Sufficient for IL-4’s Role in Th2 Differentiation and Cell Expansion , 2001, The Journal of Immunology.

[70]  D. Cantrell Phosphoinositide 3-kinase signalling pathways. , 2001, Journal of cell science.

[71]  G. Trinchieri,et al.  Biosynthesis and Posttranslational Regulation of Human IL-121 , 2000, The Journal of Immunology.

[72]  M. Gately,et al.  Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. , 1995, Journal of immunology.

[73]  R. Vessella,et al.  Evaluation of AFP glycosylation heterogeneity in cancer patients with AFP‐producing tumors , 1984, International journal of cancer.

[74]  A. Hershko,et al.  A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. , 1978, Biochemical and biophysical research communications.

[75]  P. Murray Macrophage Polarization. , 2017, Annual review of physiology.

[76]  S. Ha,et al.  Poster Session 4 : Immunology ; Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T Lymphocyte responses for DNA immunization , 2003 .